Zynx Health, the leader in evidence-based healthcare, announces the official launch of Zynx OncologyCare, which offers a comprehensive library of actionable order sets developed through a collaboration with the National Comprehensive Cancer Network (NCCN). The order sets are based on the NCCN Chemotherapy Order Templates™ and are consistent with the NCCN Clinical Practice Guidelines in Oncology™ and the NCCN Drugs & Biologics Compendium™.

"We are thrilled to announce the release of Zynx OncologyCare, a product that we've developed in collaboration with NCCN," said Victor Lee, MD, director of content development at Zynx Health. "We believe that Zynx OncologyCare chemotherapy order sets will enable oncology practices to streamline order entry workflow and optimize reimbursement potential." Zynx OncologyCare order sets are based on the NCCN Drugs & Biologics Compendium, which several major payers regard as a primary source for making cancer coverage determinations. By relying on Zynx OncologyCare order sets, clients can be confident about reimbursement.

Zynx OncologyCare directly addresses the complexities of appropriate chemotherapy administration, including:

- Chemotherapy dosing
- Supportive care, such as premedications and antiemetic therapy
- Monitoring and hold parameters, with applicable laboratory orders
- Safety parameters and special instructions

Clients can access the order sets using Zynx's Web-based software, AuthorSpace™. AuthorSpace streamlines the content management process by enabling clients to access, customize, share, and update order sets. Cancer centers can then deploy the order sets at the point of care, either in paper form or on an intranet, or to an electronic medical record (EMR) system.

"The NCCN Chemotherapy Order Templates, which are the basis for Zynx OncologyCare, can enhance patient safety by helping clinicians standardize patient care, reduce medication errors, and anticipate and manage adverse events," said William T. McGivney, PhD, chief executive officer of NCCN. "NCCN is pleased to collaborate with Zynx Health on this new product that promotes the safe use of drugs and biologics in cancer care."

Source
National Comprehensive Cancer Network